A corneal-penetrating eye drop formulation for enhanced therapeutic efficacy of soft corticosteroids against anterior uveitis

Huang, Wen-Chia; Cheng, Felice; Wang, Yen‐Jen; Chen, Chia‐Ching; Hu, Tsan-Lin; Yin, Shao-Chan; Liu, Chih-Peng; Yu, Neng-Chang; Huang, Kuo-Kuei; Lin, Meng-Nan

doi:10.1016/j.jddst.2019.101341

Cited by 4 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent research on ocular formulations containing CDs include: sustained-delivery eye drops [ 90 , 91 ]; in situ gelling systems [ 92 , 93 ]; mucoadhesive hydrogels [ 94 , 95 ]; CD/drug-loaded contact lenses [ 96 , 97 ]; and micro and nanosystems [ 86 , 98 , 99 ]. Also, CD-based formulations have shown potential to treat eye posterior segment diseases, such as diabetic retinopathy and age-related macular degeneration, which are commonly treated by intravitreal drug injections [ 100 ].…”

Section: Resultsmentioning

confidence: 99%

Technological evolution of cyclodextrins in the pharmaceutical field

Rincón-López

Almanza-Arjona

Riascos

et al. 2021

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

We herein disclose how global cyclodextrin-based pharmaceutical technologies have evolved since the early 80s through a 1998 patents dataset retrieved from Derwent Innovation Index. We used text-mining techniques based on the patents semantic content to extract the knowledge contained therein, to analyze technologies related to the principal attributes of CDs: solubility, stability, and taste-masking enhancement. The majority of CDs pharmaceutical technologies are directed toward parenteral aqueous solutions. The development of oral and ocular formulations is rapidly growing, while technologies for nasal and pulmonary routes are emerging and seem to be promising. Formulations for topical, transdermal, vaginal, and rectal routes do not account for a high number of patents, but they may be hiding a great potential, representing opportunity research areas. Certainly, the progress in materials sciences, supramolecular chemistry, and nanotechnology, will influence the trend of that, apparently neglected, research. The bottom line, CDs pharmaceutical technologies are still increasing, and this trend is expected to continue in the coming years. Patent monitoring allows the identification of relevant technologies and trends to prioritize research, development, and investment in both, academia and industry. We expect the scope of this approach to be applied in the pharmaceutical field beyond CDs technological applications.

show abstract

Section: Resultsmentioning

confidence: 99%

Technological evolution of cyclodextrins in the pharmaceutical field

Rincón-López

Almanza-Arjona

Riascos

et al. 2021

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

show abstract

“…17 Due to the entrapment of corticosteroids in cubosomes, ocular irritation is overcome and improves patient compliance. 18 Cubosomes can also protect the drugs from chemical and enzymatic degradation at an ocular site. 19 Additionally, the polymers used for the formulation of cubosomes form twisted 3D structures with continuous hydrophilic and hydrophobic regions.…”

Section: Introductionmentioning

confidence: 99%

Cubosome-based Corticosteroidal Drug Delivery System for Sustained Ocular Delivery: A Pharmacokinetic Investigation

Chakorkar,

Mulla

2024

Ind. J. Pharm. Edu. Res

View full text Add to dashboard Cite

Background: Fluorometholone is an anti-inflammatory glucocorticoid. It has been used in various ocular inflammatory as well as infectious conditions. Opting for sustained release in ocular drug delivery is a favorable option for managing ocular diseases. To improve efficacy and to overcome side effects, fluorometholone was encapsulated in cubosomal vesicles. Aim: In this study, fluorometholone-loaded cubosomal vesicles were prepared using top-down techniques and applying the QbD approach. The optimized formulation releases the drug in a sustained release manner. Materials and Methods: The optimization of cubosomal vesicles was conducted using a 3 2 -CDD. The independent parameter was selected: Concentration of both polymers Glyceryl monooleate (GMO) and Poloxamer 407 (P407), sonication time. The desired property for five important critical attributes of fluorometholone-loaded cubosome vesicles, namely % entrapment efficiency, Cumulative drug release, particle size, polydispersity index and Viscosity. Results and Discussion:The optimized formulation suggested by the central composite design was the concentration of GMO and P407; sonication times were 0.36 g, 0.46 g and 8 min, respectively. The optimized formulation exhibited % entrapment efficiency, % Cumulative drug release, particle size, polydispersity index and Viscosity were 82.89%, 88.33%, 137.7 µn, 0.22 and 169.3 m.Pas. The results confirm that implementing a QbD approach in cubosomal design leads to demonstrably improved formulation outcomes. The optimized batch was used for further evaluation like pH and Refractive index, Morphological feature evaluation, Release kinetics study, Test for sterility and stability and in vivo pharmacokinetic study. Conclusion: The present work confirms the improved ocular bioavailability of fluorometholone-loaded cubosomes.

show abstract